Tags

Type your tag names separated by a space and hit enter

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Antimicrob Agents Chemother. 2017 08; 61(8)AA

Abstract

There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002).

Authors+Show Affiliations

Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA mhn5@pitt.edu. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Department of Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28559250

Citation

Shields, Ryan K., et al. "Ceftazidime-Avibactam Is Superior to Other Treatment Regimens Against Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia." Antimicrobial Agents and Chemotherapy, vol. 61, no. 8, 2017.
Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8).
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017). Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 61(8). https://doi.org/10.1128/AAC.00883-17
Shields RK, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens Against Carbapenem-Resistant Klebsiella Pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8) PubMed PMID: 28559250.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. AU - Shields,Ryan K, AU - Nguyen,M Hong, AU - Chen,Liang, AU - Press,Ellen G, AU - Potoski,Brian A, AU - Marini,Rachel V, AU - Doi,Yohei, AU - Kreiswirth,Barry N, AU - Clancy,Cornelius J, Y1 - 2017/07/25/ PY - 2017/04/26/received PY - 2017/05/19/accepted PY - 2017/6/1/pubmed PY - 2018/4/18/medline PY - 2017/6/1/entrez KW - Klebsiella pneumoniae KW - Klebsiella pneumoniae carbapenemase KW - bacteremia KW - carbapenem-resistant Enterobacteriaceae KW - ceftazidime-avibactam KW - clinical success JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 61 IS - 8 N2 - There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant Klebsiella pneumoniae bacteremia was associated with higher rates of clinical success (P = 0.006) and survival (P = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (P = 0.002). SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/28559250/Ceftazidime_Avibactam_Is_Superior_to_Other_Treatment_Regimens_against_Carbapenem_Resistant_Klebsiella_pneumoniae_Bacteremia_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=28559250 DB - PRIME DP - Unbound Medicine ER -